Literature DB >> 10896313

Structure-based design of potent CDK1 inhibitors derived from olomoucine.

P Furet1, J Zimmermann, H G Capraro, T Meyer, P Imbach.   

Abstract

Cyclin-dependent kinase 1 (CDK1), an enzyme participating in the regulation of the cell cycle, constitutes a possible target in the search for new antitumor agents. Starting from the purine derivative olomoucine and following a structure-based approach, potent inhibitors of this enzyme were rapidly identified. The molecular modeling aspects of this work are described.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10896313     DOI： 10.1023/a:1008115004986

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN： 0920-654X            Impact factor:   3.686


  19 in total

1.  Chemical inhibitors of cyclin-dependent kinases.

Authors:  L Meijer
Journal:  Trends Cell Biol       Date:  1996-10       Impact factor: 20.808

2.  Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.

Authors:  L Havlícek; J Hanus; J Veselý; S Leclerc; L Meijer; G Shaw; M Strnad
Journal:  J Med Chem       Date:  1997-02-14       Impact factor: 7.446

Review 3.  The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases.

Authors:  L N Johnson; E D Lowe; M E Noble; D J Owen
Journal:  FEBS Lett       Date:  1998-06-23       Impact factor: 4.124

4.  Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.

Authors:  M Legraverend; O Ludwig; E Bisagni; S Leclerc; L Meijer
Journal:  Bioorg Med Chem Lett       Date:  1998-04-07       Impact factor: 2.823

Review 5.  Cyclin-dependent kinases: engines, clocks, and microprocessors.

Authors:  D O Morgan
Journal:  Annu Rev Cell Dev Biol       Date:  1997       Impact factor: 13.827

Review 6.  Viewpoint: putting the cell cycle in order.

Authors:  K Nasmyth
Journal:  Science       Date:  1996-12-06       Impact factor: 47.728

7.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.

Authors:  W F De Azevedo; S Leclerc; L Meijer; L Havlicek; M Strnad; S H Kim
Journal:  Eur J Biochem       Date:  1997-01-15

8.  Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

Authors:  W F De Azevedo; H J Mueller-Dieckmann; U Schulze-Gahmen; P J Worland; E Sausville; S H Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

9.  Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.

Authors:  R Hoessel; S Leclerc; J A Endicott; M E Nobel; A Lawrie; P Tunnah; M Leost; E Damiens; D Marie; D Marko; E Niederberger; W Tang; G Eisenbrand; L Meijer
Journal:  Nat Cell Biol       Date:  1999-05       Impact factor: 28.824

10.  Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2.

Authors:  A M Lawrie; M E Noble; P Tunnah; N R Brown; L N Johnson; J A Endicott
Journal:  Nat Struct Biol       Date:  1997-10
View more
  3 in total

1.  Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching.

Authors:  P Furet; T Meyer; P Mittl; H Fretz
Journal:  J Comput Aided Mol Des       Date:  2001-05       Impact factor: 3.686

Review 2.  Clinically Applicable Inhibitors Impacting Genome Stability.

Authors:  Anu Prakash; Juan F Garcia-Moreno; James A L Brown; Emer Bourke
Journal:  Molecules       Date:  2018-05-13       Impact factor: 4.411

Review 3.  In silico pharmacology for drug discovery: applications to targets and beyond.

Authors:  S Ekins; J Mestres; B Testa
Journal:  Br J Pharmacol       Date:  2007-06-04       Impact factor: 8.739
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.